1207-P: Gestational Diabetes Mellitus (GDM)—Outcomes for Normal-Weight Individuals

Abstract

Excess body weight is associated with GDM, and BMI ≥ 25kg/m2 is often used as a criterion in risk factor-based screening programs. However, individuals with a normal BMI account for a significant proportion of those diagnosed with GDM (20-60% depending on the population studied), and comparative clinical outcome data are limited. Our aim was to assess pregnancy outcomes for people with GDM and a baseline BMI < 25kg/m2, compared to a reference group with GDM and a BMI of 25-30kg/m2. Included subjects attended our institution for prenatal care from 2018-22 and GDM was diagnosed using universal screening and Carpenter and Coustan criteria. We identified 524 individuals with a BMI < 25kg/m2 and 705 with a BMI 25-30kg/m2. Those with a BMI <25 kg/m2 were younger (22 v 28 years, p<0.001), and a higher proportion identified as Asian (15.5% v 9.22%; p=0.04). Table 1 contains pregnancy outcomes. Those with a BMI <25kg/m2 were less likely to receive pharmacological GDM therapy, but their infants had a higher rate of neonatal ICU admission. Postpartum, those with a BMI <25kg/m2 were less likely to have an oral glucose tolerance test but were at similar risk of glucose intolerance. These findings suggest that normal weight women with GDM may experience higher risk of adverse outcomes compared to their overweight counterparts. These data support universal screening and will be used to inform patients on their risk profile and improve postpartum screening. Disclosure M.Moazzami: None. N.Venkatesan: None. K.Sankaran rajagopalan: None. A.Vella: Advisory Panel; Rezolute, Inc., Consultant; Crinetics Pharmaceuticals, Inc., Hanmi Pharm. Co., Ltd., Zealand Pharma A/S, Other Relationship; Novo Nordisk. A.M.Egan: None. Funding National Institutes of Health (DK092721, HD065987)